Snapshot from Jun 25, 2026 at 22:38 UTC. For live data and tracking: View Live
Entities / People / Thomas Equels
Person

Thomas Equels

Tracked across 1 events · 10 articles · First seen Jun 01, 2026 · Last active Jun 08, 2026

Sentiment
60
Attention
4
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the NewsDesk Dashboard
Events (1)
4 60
Tech
AIM ImmunoTech reports positive DURIPANC progress
AIM ImmunoTech Inc. reported positive mid-year interim clinical progress from its Phase 2 DURIPANC study, evaluating Ampligen (rintatolimod) in combination with AstraZeneca's Imfinzi (durvalumab) for metastatic pancreatic cancer. The company also announced the ahead-of-schedule enrollment…
Impact: Thomas Equels, CEO of AIM ImmunoTech Inc., provided statements on the positive progress and future plans for Ampligen, highlighting the potential for improved patient outcomes and company growth.
Jun 01, 2026 · 10 articles
NEWSDESK
Track Thomas Equels live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.